Zacks Research Brokers Reduce Earnings Estimates for Qiagen

Qiagen (NYSE:QGEN) – Stock analysts at Zacks Research reduced their Q4 2025 earnings per share estimates for shares of Qiagen in a report issued on Wednesday, February 26th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.63 per share for the quarter, down from their previous estimate of $0.64. The consensus estimate for Qiagen’s current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen’s Q1 2026 earnings at $0.51 EPS and FY2027 earnings at $2.69 EPS.

Qiagen (NYSE:QGEN) last announced its earnings results on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%.

Several other brokerages also recently weighed in on QGEN. Robert W. Baird downgraded shares of Qiagen from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $52.00 to $42.00 in a report on Wednesday, February 19th. Baird R W cut Qiagen from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 19th. UBS Group dropped their price objective on Qiagen from $50.00 to $48.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. Jefferies Financial Group reissued a “buy” rating and issued a $52.50 target price (up previously from $40.83) on shares of Qiagen in a report on Tuesday, December 10th. Finally, Morgan Stanley restated an “equal weight” rating and set a $46.67 target price (down from $48.61) on shares of Qiagen in a research report on Monday, January 6th. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $47.71.

Qiagen Price Performance

Shares of NYSE QGEN opened at $38.38 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.61 and a quick ratio of 3.09. The company has a market cap of $8.51 billion, a PE ratio of 106.86, a P/E/G ratio of 2.39 and a beta of 0.36. The stock has a fifty day moving average price of $42.81 and a 200 day moving average price of $42.94. Qiagen has a 1-year low of $38.29 and a 1-year high of $49.30.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in QGEN. Geneos Wealth Management Inc. increased its holdings in Qiagen by 41.5% during the 4th quarter. Geneos Wealth Management Inc. now owns 856 shares of the company’s stock valued at $38,000 after acquiring an additional 251 shares in the last quarter. Zurich Insurance Group Ltd FI increased its stake in shares of Qiagen by 5.7% during the 3rd quarter. Zurich Insurance Group Ltd FI now owns 5,291 shares of the company’s stock worth $239,000 after purchasing an additional 287 shares in the last quarter. National Bank of Canada FI increased its stake in shares of Qiagen by 1.2% during the 3rd quarter. National Bank of Canada FI now owns 25,636 shares of the company’s stock worth $1,155,000 after purchasing an additional 308 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its position in shares of Qiagen by 3.6% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 9,816 shares of the company’s stock worth $438,000 after purchasing an additional 341 shares during the last quarter. Finally, Pitcairn Co. lifted its stake in Qiagen by 5.3% in the 4th quarter. Pitcairn Co. now owns 6,996 shares of the company’s stock valued at $312,000 after buying an additional 354 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.